COMBINED TREATMENT WITH BORTEZOMIB & DACARBAZINE

与硼替佐米联合治疗

• 批准号: 7605017
• 负责人: John David Roberts
• 金额: $ 1.47万
• 依托单位: VIRGINIA COMMONWEALTH UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-20 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7605017
• 关键词: Bortezomib; Combined Modality Therapy; Computer Retrieval of Information on Scientific Projects Database; Dacarbazine; Dose; Funding; Grant; Institution; Maximum Tolerated Dose; Measures; Rate; Reaction Time; Research; Research Personnel; Resources; Source; Time; Treatment Efficacy; United States National Institutes of Health; melanoma; response; sarcoma; tumor

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The hypotheses is that combined treatment with bortezomib and dacarbazine will result in enhanced therapeutic efficacy in melanoma and soft tissue sarcoma. The specific Aims are to : (1) Determine the recommended doses for the combination dacarbazine and bortezomib administered weekly; (2) Determine the maximum tolerated dose combination; and (3) Observe anti-tumor activity in terms of response rate(s), duration of response, time to progression, and time on treatment (a measure of both antitumor activity and treatment tolerance).

这个子项目是众多研究子项目之一